Sign in
CompletedNo phase

BAR As a Mortality Predictor in Septic AKI

Key facts

Who runs it
Ain Shams University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
64 people enrolled
Started
25 Sept 2023
Ended
25 Sept 2024
Type of study
Observational
Record updated
17 February 2025

Who can take part

Age
18 years to 60 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • 18 - 60 years of age
  • Fulfilled the diagnostic criteria of Sepsis 3.0 (defined as a suspected or confirmed infection with a sequential organ failure assessment (SOFA) score of 2 or higher)
  • Developed AKI during hospitalization according to Kidney Disease: Improving Global Outcomes (KDIGO) guideline

Who cannot take part

  • Receiving renal replacement therapy at the time of admission
  • Diagnosis with chronic kidney disease
  • Diagnosis with liver failure
  • Patients who had received Human serum Albumin infusion 3 days before ICU admission
  • ICU length of stay<24 h
  • AKI occurred before current hospital admission
  • AKI is supposed to be secondary to causes other than sepsis
  • Pregnant or lactating
  • There was insufficient data for analysis

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to investigate the prognostic value of Blood Urea Nitrogen to serum Albumin ratio in septic Acute Kidney Injury patients Follow-up will be conducted for all enrolled patients for 30 days from admission to record mortality and the cause of death.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Role of Blood Urea Nitrogen to Serum Albumin Ratio in the Prediction of Mortality in Septic Acute Kidney Injury Patients
Record updated
17 February 2025